Company intelligence / Profile preview

ImmunoRx Pharma

Wilmington, Delaware, United Statespitchbook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ImmunoRx Pharma is developing a first-in-class antibody targeting a novel pathway in chronic inflammation and autoimmunity. Its lead candidate, IRX-010, is currently in Phase 1 clinical trials for inflammatory diseases including ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. The company aims to achieve proof-of-concept for this biologic therapy.

Therapeutic areas: GastroenterologyImmunology
Modalities: AntibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

IRX-010

Unknown

Partnerships

TVM Capital Life Science (investor/partner)

Beyond the preview

Go deeper on ImmunoRx Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoRx Pharma.

Explore the full profile